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Abstract  
Aims: The present study analyzes molecular characteristics of the locus coeruleus (LC) and 
projections to the amygdala and hippocampus at asymptomatic early and middle Braak 
stages of neurofibrillary tangle (NFT) pathology.  
Methods: Immunohistochemistry, whole transcriptome arrays and RT-qPCR in LC, and 
western blotting in hippocampus and amygdala in a cohort of asymptomatic individuals at 
stages I-IV of NFT pathology were used.  
Results: NFTs in the LC increased in parallel with co-localized expression of tau-kinases; 
increased neuroketal adducts and decreased superoxide dismutase 1 in neurons with hyper-
phosphorylated tau, and decreased VDAC in neurons containing truncated tau were found. 
These were accompanied by increased microglia and AIF1, CD68, PTGS2, IL1β, IL6 and 
TNF-α gene expression. Whole transcriptome arrays revealed up-regulation of genes coding 
for proteins associated with heat shock protein binding and genes associated with ATP 
metabolism; and down-regulation of genes coding for DNA-binding proteins and of members 
of the Small Nucleolar RNAs family, at stage IV when compared with stage I. Tyrosine 
hydroxylase (TH) immunoreactivity was preserved in neurons of the LC, but decreased TH 
and increased α2A adrenergic receptor protein levels were found in the hippocampus and the 
amygdala.  
Conclusions: Complex alteration of several metabolic pathways occurs in the LC 
accompanying NFT formation at early and middle asymptomatic stages of NFT pathology. 
Dopaminergic/noradrenergic denervation and increased expression of α2A adrenergic 
receptor in the hippocampus and amygdala occur at first stages of NFT pathology, 
suggesting compensatory activation in the face of decreased adrenergic input occurring 
before clinical evidence of cognitive impairment and depression. 
 
Key words: Alzheimer’s disease, locus coeruleus, amygdala, hippocampus, tau, tyrosine 
hydroxylase, α2A adrenergic receptor, mitochondria, transcriptome, heat shock proteins, 
protein metabolism, small nucleolar RNAs 
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Introduction 
Alzheimer's disease (AD), the most common cause of cognitive impairment in the elderly, is 
a progressive neurodegenerative disorder lasting for decades which is characterized 
morphologically by accumulation of β-amyloid in the neuropil forming fibrillar diffuse deposits 
and senile plaques; β-amyloid deposits in blood vessels leading to amyloid angiopathy; and 
intraneuronal accumulation of hyper-phosphorylated and truncated 3Rtau and 4Rtau as the 
major component of neurofibrillary tangles (NFTs), neuropil threads, and dystrophic neurites 
of senile plaques [1-3]. 
These morphological alterations have a particular pattern of distribution which extends to 
most of the brain along with disease progression [4-7] paralleling the progressive 
appearance of clinical symptoms [8-10]. Clinical and pathological changes do not progress in 
the same way in all individuals; about 85% of the population aged 65 has brain lesions 
consistent with early changes of AD, yet only about 5% have reached thresholds leading to 
severe cognitive impairment and dementia (clinical stages of the neurodegenerative 
process) [11, 12]. However, 25% of the population at the age of 85 suffers from dementia of 
Alzheimer type [12]. 
The locus coeruleus (LC) is a pontine nucleus containing the largest group of noradrenergic 
neurons in the central nervous system [13, 14]. While the rostral portion of the LC innervates 
mostly forebrain structures such as the hippocampus and cerebral cortex, the caudal portion 
innervates mainly hindbrain regions [15-18]. The LC is the only noradrenergic nucleus 
innervating the cerebral cortex [19] whereas the amygdala also receives projections from the 
lateral brainstem tegmentum [20]. The LC receives input from various regions of the brain 
[21]. All these neuronal networks display the LC as a hub nucleus implicated in superior 
functions such as arousal, attention, wake-sleep cycles, emotional states, cognition, memory 
and learning, regulation of blood flow, motor coordination, neuroinflammation, neuronal 
survival, and neurogenesis [14, 22-28]. 
Noradrenaline released from the LC acts at specific synapses through α1-, α2- or β-
adrenoceptors [29, 30]. Activation of α1-adrenoceptors generally leads to excitation, and 
there is some evidence that β-adrenoceptors are also excitatory. In contrast, activation of α2-
adrenoceptors leads to inhibition, including inhibition of the noradrenergic neurons 
themselves through autoreceptors.  
The LC is the main noradrenergic nucleus affected in AD [31]. Involvement of the LC at 
advanced stages of AD has been recognized for decades [14, 32-37]. Considering a 
percentage of neuron loss of about 70% at terminal stages of the disease [33, 36], it is 
conceivable that many functions regulated by the LC are severely dampened in advanced 
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AD. However, the LC, together with raphe nuclei, is one the first regions of the brain showing 
NFTs in the context of AD-related pathology [38-42].  
Based on this scenario, the present study was focused on the LC at the first asymptomatic 
Braak stages of NFT pathology in an attempt to 1: define characteristics of tau 
phosphorylation, configuration and truncation, associated expression of tau kinases, proteins 
involved in energy metabolism, oxidative stress and responses, tyrosine hydroxylase (TH) 
immunoreactivity, and local synapses in the LC; 2: assess the impact of these alterations of 
the LC on the expression of noradrenergic receptors and TH in the hippocampus and 
amygdala; and 3: unveil altered gene expression to identify altered pathways in LC 
associated with early stages of NFT pathology using whole transcription arrays.  
 
 
Materials and methods 
Human brain samples 
Human brain samples were obtained from the Institute of Neuropathology Brain Bank (HUB-
ICO-IDIBELL biobank) following the guidelines of the Spanish legislation on this matter (Real 
Decreto Autorización y Funcionamiento de Biobancos, Ministry of Science and Innovation: 
1716/2011) and the approval of the local ethics committee of the Bellvitge University 
Hospital-IDIBELL.   
No individuals in the present series had neurological complaints; all of them were 
categorized as cognitively well preserved at the time of admission to the hospital; depression 
was not reflected in the clinical records of any case. All of them were admitted and died in 
the hospital from various non-neurological diseases. NFT pathology was an incidental 
observation during the post-mortem neuropathological study. However, it is worth stressing 
that clinical histories were not directed to exhaustively analyze ‘minor’ neurological and 
neuropsychological changes such as recent modifications in mood, wake-sleep cycle 
disturbances, impairment of attention, and learning capacity. Therefore, these symptoms 
might have been present without being recorded in some individuals. 
Neuropathologic diagnosis was made following the Braak and Braak staging for NFTs 
adapted to paraffin sections [4, 43], Thal phases for β-amyloid score [5], and CERAD stages 
of senile plaques [44]. Cases with combined pathologies were excluded from the present 
study. Only cases with concomitant mild small vascular disease were accepted. Cases with 
evident long agonic state, hypoxia, or seizures were excluded. 
Two series of cases were used. For morphological and immunohistochemical studies, 
categorization of cases was as follows: Braak stage I of NFT pathology: n = 21, 10 men, 11 
women, age 66.7 ± 6.68 years; stage II: n = 19, 12 men, 7 women, age 70.3 ± 7.83 years; 
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stage III: n = 15, 5 men, 10 women, age 77.6 ± 6.83; and stage IV, n = 12, 8 men, 4 women, 
age 77.75 ± 8.01 years. The post-mortem delay was 7.4 ± 5.1 hours (between 2 h and 21 h). 
The purpose of the first series was to analyze changes linked to tau phosphorylation in LC; 
control cases without NFT pathology were not necessary.    
The second series of cases was used for biochemical studies including whole transcriptome 
arrays and RT-qPCR validation in LC, and determination of protein levels of tyrosine 
hydroxylase (TH) and α2A adrenergic receptor (α2A-AR) with western blotting in the 
hippocampus and amygdala. Each of these studies was carried out in all cases. 
Categorization of cases was as follows: middle-aged individuals with no clinical symptoms 
and without neuropathological lesions (no β-amyloid deposits, NFT stage 0) called MA: n = 
10, 6 men, 4 women, age 51.3 ± 5.9; stage I: n = 8, 7 men, 1 women, age 66.2 ± 6.45 years; 
stage II: n = 4, 1 men, 3 women, age 65.5 ± 9.60 years; stage III: n = 8, 6 men, 2 women, 
age 76.7 ± 9.20; and stage IV, n = 5, 4 men, 1 women, age 83.8 ± 5.93 years. The post-
mortem delay was 6.42 ± 3.64 hours (between 2 h and 14 h) (Supplementary Table I). The 
purpose of the second series was to assess changes in LC at early and middle stages of 
NFT pathology compared with MA individuals with no NFT pathology used as controls. Thal 
phases varied from 0 to 1 and neuritic plaque score CERAD from 0 to 1 in cases with NFT 
pathology. β-amyloid deposits in LC were not found in any cases.     
Immunohistochemistry 
De-waxed sections, 4μm thick, of the LC were processed for immunohistochemistry. The 
sections were boiled in citrate buffer (20 min) to retrieve tau antigenicity. Endogenous 
peroxidases were blocked by incubation in 10% methanol-1% H2O2 solution (15 min) 
followed by 3% normal horse serum solution. Then the sections were incubated at 4ºC 
overnight with one of the primary antibodies listed in Supplementary Table II. Following 
incubation with the primary antibody, the sections were incubated with EnVision + system 
peroxidase (Dako, DK) for 30 min at room temperature. The peroxidase reaction was 
visualized with diaminobenzidine and H2O2. Control of the immunostaining included omission 
of the primary antibody; no signal was obtained following incubation with only the secondary 
antibody.  
Double-labeling immunofluorescence and confocal microscopy  
De-waxed sections, 4 microns thick, were stained with a saturated solution of Sudan black B 
(Merck, DE) for 15 min to block the autofluorescence of lipofuscin granules present in cell 
bodies, and then rinsed in 70% ethanol and washed in distilled water. The sections were 
incubated at 4ºC overnight with combinations of primary antibodies. After washing, the 
sections were incubated with Alexa488 or Alexa546 (1:400, Molecular Probes, US) 
fluorescence secondary antibodies against the corresponding host species. Nuclei were 
stained with DRAQ5TM (1:2,000, Biostatus, GB). After washing, the sections were mounted 
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in Immuno-Fluore mounting medium (ICN Biomedicals, US), sealed, and dried overnight. 
Sections were examined with a Leica TCS-SL confocal microscope. 
Quantification of morphological studies 
Quantification was carried out in the rostral part of the LC within the dorsolateral pontine 
tegmentum at the level of the lower segment of the cerebral aqueduct of Sylvius just before 
the IV ventricle [45]. Neurons with NFTs as revealed with the antibody AT8 were counted in 
all cases of the morphological series (n = 67), using three non-consecutive sections per case 
separated by 50 microns at a magnification of x200; the total number of neurons was 
estimated in the same sections, which were slightly counterstained with haematoxylin. 
Unbiased stereological estimation of the total number of neurons [46] was not possible in the 
present series as tissue blocks did not contain the whole LC. However, this limitation had no 
substantial implications in the purposes at hand, as discussed below. 
About 5,360 neurons were counted in total. Results were expressed as the percentage of 
neurons with NFTs in relation to the total number of LC neurons at stages I, II, III, and IV of 
NFT pathology. Mean values for each group were compared with one-way analysis of 
variance (ANOVA) followed by post-hoc Tukey’s multiple comparison test, and differences 
were considered statistically significant at p < 0.05; p < 0.01; and p < 0.001.   
The estimation of co-localization of two proteins labeled with specific antibodies and 
examined with the confocal microscope was assessed by counting the number of cells 
expressing both antigens in relation to the number of cells stained with each one of the 
antibodies in five selected fields per section and three sections in every case. The number of 
cells counted varied depending on the size of the population bearing the most abundant 
assessed protein. The values were expressed as the percentage of the more abundant 
protein because the less abundant protein represented a subset of the former (i.e., 
percentage of P-tauThr181-positive neurons co-expressing Alz50). 
Total membrane preparation 
Frozen samples of the hippocampus and amygdala were homogenized in ice-cold 10 mM 
Tris HCl, pH 7.4, 1 mM EDTA, 300 mM KCl buffer containing a protease inhibitor cocktail 
(Roche Molecular Systems, USA) using a Polytron for three periods of 10 s each. The 
homogenate was centrifuged for 10 min at 1,000xg. The resulting supernatant was 
centrifuged for 30 min at 12,000xg. The membranes were dispersed in 50mM Tris HCl (pH 
7.4) and 10mM MgCl2, washed, and re-suspended in the same medium as described 
previously [47]. Protein concentration was determined using the BCA protein assay kit 
(Thermo Fisher Scientific, Inc., Rockford, IL, USA) and 80μg of protein were used for 
Immunoblot. Plasmids and transfection used to verify the characteristics of α2A-AR 
expressed in HEK-293T cells are shown in Supplementary data 2.  
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Gel electrophoresis and immunoblotting 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS/PAGE) was per- formed 
using 10% polyacrylamide gels. Proteins were transferred to PVDF membranes using a 
semidry transfer system and immunoblotted with the indicated antibody, and then with HRP-
conjugated rabbit anti-goat (1:30,000) or goat anti-rabbit IgG (1:30,000). The 
immunoreactive bands were developed using a chemiluminescent detection kit (Pierce) and 
the Amersham Imager 600 (GE Healthcare Europe GmbH, Barcelona, Spain). 
Whole-transcriptome arrays 
Synthesis and hybridization of cRNA 
RNA from frozen LC was extracted following the instructions of the supplier (Rneasy Mini Kit, 
Qiagen® GmbH, Hilden, GE). RNA integrity number (RIN) and 28S/18S ratios were 
determined with the Agilent Bioanalyzer (Agilent Technologies Inc, Santa Clara, CA, USA) to 
assess RNA quality; RNA concentration was evaluated using a NanoDrop™ 
Spectrophotometer (Thermo Fisher Scientific, Carlsbad, CA, USA). RIN (RNA integrity 
number) values are presented in Supplementary Table I. Suitability of such cases for mRNA 
expression studies was tested by RT-qPCR using different probes. The outliers were 
detected using the GraphPad software QuickCalcs (p< 0.05).   
Details of microarray hybridization are shown in Supplementary data 3. The method of RNA 
sample preparation was based on the original T7 in vitro transcription technology known as 
the Eberwine or RT-IVT method [48].    
Microarray data analysis 
Microarray data quality control, normalization, and filtering were performed using 
Bioconductor packages in R programming environment for genes [49]. Processing of raw 
data for the non-coding regions was performed using Affymetrix Transcription Array Console 
software (Santa Clara, CA, USA). Cofactor neuritic plaques and gender (M or W) were 
considered in the analysis as well as the experimental batch (1 or 2). Genes were first 
selected based upon their experimental values using a test for differential expression 
between two classes (Student’s t-test) or a clustering method for co-expressed genes 
(ANOVA one-way test). Genes were considered differentially expressed if they showed an 
absolute fold change >1.2 in combination with an unadjusted p-value ≤ 0.05, as differentially 
expressed genes obtained from the  microarray were lower than currently selected fold 
change values between 2.0 and 2.5  [50].  
Microarray data post-analysis: Gene ontology (GO) and Ingenuity pathway analysis 
(IPA) 
Once a list of differentially expressed genes was identified from microarrays, the selection of 
putative candidates was analyzed for biological significance using a gene enrichment 
analysis against Gene ontology (GO) through bioconductor packages in R programming 
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using p<0.05 as the cut-off point to determine whether GO database was significantly 
enriched. The core analysis function included in IPA (Ingenuity System Inc, CA, USA) was 
used to interpret the data in the context of biological processes, pathways, and networks.  
Validation of microarray data 
Retro-transcription polymerase chain reaction 
Retro-transcription reaction of RNA samples selected on the basis of their RIN values was 
carried out with the High-Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA, 
USA) following the guidelines provided by the manufacturer and using Gene Amp 9700 PCR 
System thermocycler (Applied Biosystems). One RNA was processed in parallel in the 
absence of reverse transcriptase to rule out DNA contamination.  
Quantitative real-time polymerase chain reaction (RT-qPCR) 
RT-qPCR assays were conducted in duplicate on cDNA samples obtained from the retro-
transcription reaction diluted 1:10 in 384-well optical plates (Kisker Biotech, Steinfurt, GE) 
utilizing the ABI Prism 7900 HT Sequence Detection System (Applied Biosystems). TaqMan 
probes (Thermo Fisher Scientific) used in the study are listed in Supplementary Table III. 
Selection of house-keeping genes was made on the basis of their preservation levels in 
human post-mortem brain [51, 52]. ∆∆CT values were obtained from the ∆CT of each 
sample minus the mean ∆CT of the population of control samples (calibrator samples). The 
fold-change was determined using the equation 2-∆∆CT. Mean fold-change values in each 
group were analyzed with the ANOVA one-way test using the Statgraphics Statistical 
Analysis and Data Visualization Software version 5.1.  
Statistical analysis 
Results were analyzed statistically with SPSS 19.0 (SPSS Inc., USA) software and 
GraphPad PRISM (GraphPad Software, Inc.) software. Data were presented as mean ± 
standard error of the mean (SEM). Pearson’s correlation method was used to assess a 
possible linear association between two continuous variables in the studied samples. Data 
were compared with two-tailed unpaired student t-test or one-way analysis of variance 
(ANOVA) followed by post-hoc Tukey’s multiple comparison test when necessary. 
Differences between groups were considered statistically significant at * p<0.05, ** p<0.01 
and *** p<0.001. Tendencies were considered at # p<0.1. 
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Results 
General pathology of the LC: tau phosphorylation and tau-kinases  
The number of neurons with hyper-phosphorylated tau deposition was first analyzed in three 
non-consecutive sections of the rostral part of the LC at the level of the lower segment of the 
cerebral aqueduct of Sylvius in every case stained with the antibody AT8 which recognizes 
tau phosphorylation sites Ser202/Thr205, and expressed as the number of positive cells in 
relation to the total number of neurons per section (about 5,360 LC neurons counted in 
total). The number of AT8-immunoreactive neurons increased with age and stage 
progression from about 1% at stage I of NFT pathology to about 15% at stage IV (Fig 1A). 
Abnormal tau deposition was positive with tau-100 and 3Rtau and 4Rtau antibodies and with 
phospho-specific anti-tau antibodies P-tauThr181, P-tauSer262, P-tauSer422, and double-
phosphorylated at Ser396/Ser404 (antibody PHF1). Most of them were also stained with 
conformation-specific antibodies Alz50 with tau modifications at amino acids 5-15, but only a 
minority of neurons were labeled with the antibody tau-C3 that recognizes truncated tau at 
aspartic acid 421 (Fig. 1B). Double-labeling immunofluorescence and confocal microscopy 
disclosed that 100% of P-tauThr181-positive neurons were stained with AT8 antibodies and 
about 80% of P-tauThr181-positive neurons with Alz50 antibodies (total number of P-
tauThr181-positive neurons counted: 236). Double-labeling immunofluorescence revealed 
that only about 5% of P-tauThr181-positive neurons were stained with tau-C3 antibody (total 
number of P-tauThr181-positive neurons counted: 128). Double-labeling 
immunofluorescence identified that only about 5% of AT8-positive neurons were stained with 
anti-ubiquitin antibodies in the LC at stages III and IV (total number of AT8-positive neurons 
counted: 214) (Fig. 1C). Immunoreactivity to tau-C3 and ubiquitin in neurons was restricted 
to those neurons bearing hyper-phosphorylated tau (100% co-localization).  
Double-labeling immunofluorescence and confocal microscopy showed total co-localization 
(100%) of P-tauThr181 and MAPK/ERK-P (Thr202/Tyr204), and 100% co-localization of AT8 
and SAPK-JNK-P (Thr183/Tyr185), but 80% co-localization of AT8 and p38-P 
(Thr180/Tyr182), about 65% of AT8 and GSK-3β-P (Ser9), and about 42% P-tauThr181 and 
GSK-P (Y279/Y216) in LC from stage I to stage IV (Fig. 2). Immunoreactivity to the several 
kinases was restricted to neurons with hyper-phosphorylated tau.  
Energy metabolism, and oxidative stress damage and responses 
Antibodies against voltage-dependent anion channel (VDAC) immunostaining were used as 
a marker of mitochondrial membranes. Double-labeling immunofluorescence and confocal 
microscopy showed that a minority of LC neurons bearing hyper-phosphorylated tau had 
decreased VDAC immunoreactivity (Fig. 3Aa-c). Double-labeling immunofluorescence with 
tau-C3 antibody and anti-VDAC disclosed decreased VDAC immunoreactivity only in the 
subpopulation of neurons stained with tau-C3 antibody (Fig. 3A, d-f). 
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A decrease in superoxide dismutase 1 (SOD1) immunoreactivity was found in LC neurons 
with hyper-phosphorylated tau deposition when compared with neurons without tau in the 
same tissue section (Fig. 3B, a-c). This was accompanied by increased expression of 
neuroketal (NKT) restricted to LC neurons containing hyper-phosphorylated tau as revealed 
by double-labeling immunofluorescence and confocal microscopy (Fig. 3B, d-f). Quantitative 
studies at stages III and IV identified increased NKT immunoreactivity and decreased SOD1 
immunoreactivity in practically the totality of LC neurons stained with anti-P-tauThr181 
antibodies (total P-tauThr181-immunoractive neurons counted: 196).  
Finally, double-labeling immunofluorescence with antibodies against specific anti-
hemoglobin and AT8 showed reduced hemoglobin α and hemoglobin β/γ immunoreactivity in 
all LC neurons containing hyper-phosphorylated tau in contrast with preservation of 
immunoreactivity in neighboring LC neurons lacking abnormal hyper-phosphorylated tau 
deposits (total AT8-immunoreactive neurons assessed: 232)  (Fig. 3C, a-f). Importantly, 
erythropoietin receptor (EPOR) immunoreactivity was preserved in LC neurons with hyper-
phosphorylated tau deposition (Fig. 3C, g-i).  
Tyrosine-hydoxylase (TH) and synapses 
No modifications in TH immunoreactivity were observed in LC neurons bearing phospho-tau 
at stages I-IV of NFT pathology (Fig. 4A).  
Reduced synaptophysin-immunoreactive perineuronal dots representing synaptic contacts 
with the neuronal cytoplasm were observed in LC neurons stained with tau-C3 antibodies 
(Fig. 4B). Quantitative studies (total neurons counted without NFTs: 126; total neurons with 
NFTs counted: 28) showed a decrease of between 40% and 60% of synaptophysin-
immunoreactive dots on the cell surface of tau-C3-immunoreactive LC neurons when 
compared with LC neurons without tau-C3 in the same tissue section.  
Glial responses 
The number of astrocytes was not increased in LC at stages I-IV (data not shown). In 
contrast, a moderate increase in the number of microglial cells, as revealed with Iba-1 
antibody, was found at stages III and IV of NFT pathology. Some microglial cells adopted a 
reactive morphology with short, thick varicose branches (Fig. 5A).  
Using the same cases employed in whole transcriptome arrays, RT-qPCR showed 
significantly increased gene expression of AIF1 (which encodes Iba-1), CD68, PTGS2 
(which encodes COX2), IL1β, IL6, and TNF-α in LC at stages III and IV of NFT pathology. In 
contrast, GFAP and IL10 mRNA expression levels were not modified in LC at the same 
stages (Fig. 5B). 
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α2A-AR and TH expression levels in hippocampus and amygdala at stages I-IV of NFT 
pathology  
First, the specificity of the anti-α2A-AR antibody was validated with immunoblot detection of 
the human α2A-AR transiently expressed in HEK-293T cells. The anti-α2A-AR detected 
several broad bands of ~46, 50, 65 kDa (Supplementary Figure 1, lane: α2A-AR) which might 
correspond to non-glycosylated and glycosylated forms of the receptor, respectively [53]. As 
expected, the anti-α2A-AR did not detect any protein bands in cells transiently transfected 
with the empty vector (Supplementary Figure 1, lane: mock), thus indicating that the 
antibody was specific.  
α2A-AR expression was significantly increased in the hippocampal membrane fraction at 
stage I, but it was significantly decreased at stage IV (Fig. 6A). Interestingly, TH expression 
declined with age/disease progression, with significantly lower levels at stages III and IV in 
the same samples (Fig. 6A). The expression of α2A-AR in the amygdala was also 
significantly increased at stage I, whereas TH expression was significantly reduced at stages 
I-IV (Fig. 6B).  
Microarray analysis 
Pearson’s correlation method showed no association among post-mortem delay, RIN values, 
and gender variables. The only association was age with NFT stages. After data 
normalization and filter application, no outliers were detected, and the cofactors were not 
relevant to the analysis and therefore all samples were included. A total of 6,870 gene set 
sequences were detected across all samples. Major differences in gene profile were 
identified in LC between stage I and stage IV of NFT pathology, as graphically illustrated in 
the heat map representation of significantly regulated transcripts at a probability of <0.05 
(Fig. 7).  
A complete list of de-regulated genes is found in Supplementary Table IV.  
Enrichment analysis against GO database and ingenuity pathway analysis (IPA) 
Statistical analysis revealed the most significant enrichment analysis against go ontology 
database (p<0.05) was between stages I and IV of NFT pathology. Up-regulated genes 
coded for proteins were linked to protein folding, heat shock protein binding, and ATP 
metabolism. Down-regulated genes were linked to DNA binding and members of the small 
nucleolar RNAs family (SNOR).   
Ingenuity pathway analysis revealed up-regulated pathways corresponding to ‘neurological 
disease’, ‘hereditary disorder’, and ‘psychological disorders’. The analysis of molecular and 
cellular functions identified ‘post-translational modification mechanisms’, ‘protein folding 
system’, and ‘cellular compromise components’. Detailed analysis is shown in 
Supplementary Data 4 and Supplementary Figure 2.  
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Validation of microarray data by qRT-PCR 
We selected five genes for validation from the four main altered functional pathways 
including: 1. protein folding mechanisms HSPA1B and DNAJB1; 2. ATP metabolism ASPA6; 
3. DNA/RNA binding proteins: ID1; and 4. Non-coding small nucleolar RNAs SCARNA2. 
Stages I, II, II and IV were included in the study.  
RT-qPCR in LC samples confirmed significant up-regulation of HSPA1B and DNAJB1 at 
stage IV when compared with stage I; DNAJB1 was also significantly up-regulated at stage 
IV when compared with stage II. 
HSPA6 was significantly up-regulated at stage IV when compared with stage I.  
In contrast, ID4 was down-regulated at stage III when compared with stage I. A non-
significant trend of reduction was also observed for ID4 at AD stage IV when compared with 
stage I. 
Finally, SCARNA2 was down-regulated in LC at stages II, III, and IV when compared with 
stage I (Fig. 8).  
 
Discussion 
Cases in the present series were selected on the basis of the presence of NFTs in the LC in 
the context of early Braak staging of NFT pathology together with the absence of clinical 
symptoms related to cognitive impairment and major depression. All these cases can be 
categorized as preclinical AD stages according to the ABC classification proposed by the 
NIA/AA [54, 55]. However, it can be argued that some cases might not represent AD but 
rather primary age-related tauopathy (PART) [56, 57], because most had no β-amyloid 
plaques in the brain (particularly those at NFT stages I and II, and some at stage III), and 
lesions were restricted to tau pathology [58]. This is difficult to discuss at present, as PART 
(formerly dementia with only tangles when advanced) has also been considered part of the 
AD spectrum [59]. For this reason, herein we have avoided the term ‘AD’ and preferred to 
use the descriptive term of ‘NFT pathology categorized as Braak stages’.     
Seminal quantitative studies using unbiased methods have shown that neuron loss in the LC 
occurs at advanced stages of AD [60, 61]. This has recently been determined in a more 
comprehensive study, using the unbiased stereological method of optical fractionators, 
showing that cell loss in the LC was insignificantly small at preclinical stages of AD [62]. 
Neuron loss occurs in prodromal AD in cases with mild cognitive impairment, and neuron 
numbers markedly decrease in the LC along with progression of dementia [62]. The present 
study has taken advantage of these observations to focus on Braak stages of NFT pathology 
which do not significantly compromise the total number of neurons in the LC.        
Expression of activated kinases involved in tau phosphorylation co-localizing with hyper-
phosphorylated tau deposits in the LC has the same characteristics as those reported in 
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cerebral cortex in AD [63-66]. As described in other regions, phosphorylation of tau precedes 
altered tau conformation; tau truncation occurs only after complex tau phosphorylation, and 
tau truncation in neurons at aspartic acid 421 is needed to fully develop the cascade of NFT 
formation, including recruitment of full-length tau [67-73]. Strong association has been found 
between tau truncation at aspartic acid 421 and ubiquitin deposition in neurons in AD [74], 
and tau truncation has been proposed as an inducer of cell death via caspase activation 
[75].  
Decreased VDAC immunoreactivity, suggesting a decrease in the number of mitochondria, 
was identified only in neurons containing truncated tau as revealed with the antibody tau-C3. 
Hyper-phosphorylated tau and particularly truncated tau produce mitochondrial damage [76-
79], thus accounting for decreased numbers of mitochondria in LC neurons bearing tau-C3. 
Hyper-phosphorylated tau deposition in LC neurons is accompanied by increased neuroketal 
adducts, indicating oxidative stress damage [80], and reduced SOD1 immunoreactivity, 
suggesting reduced oxidative stress responses in the same neurons and arguing in favor of 
increased oxidative damage in the LC at early stage NFT pathology [81-83]. Haemoglobin α 
and haemoglobin β/γ immunoreactivity is also reduced in LC neurons with hyper-
phosphorylated tau deposition, as previously reported in neurons of the cerebral cortex in 
AD [84]. It has been suggested that brain haemoglobin subunits may participate in redox 
homeostasis and mitochondrial activity [85, 86]. α-haemoglobin modulates antioxidant 
defenses and facilitates tyrosine hydroxylase synthesis and activity in peripheral 
catecholaminergic cells [87].  
Microglia in the LC at middle stages of NFT pathology appear ramified with short branches, 
buds, and varicosities described as senescent microglia [88], a feature also observed in 
association with tau pathology in other brain regions [89]. These morphological changes are 
accompanied by increased mRNA expression of AIF1 (which encodes Iba-1), PTGS2 (which 
encodes COX2), IL1β, IL6 and TNF-α. 
The timing of these alterations is similar to that seen in P301S transgenic mice used as a 
model of frontotemporal lobar dementia linked to mutations in MAPT (FTLD-tau) [90] and 
differs from biochemical responses of neurons and glial cells in mouse models of β-amyloid 
deposition [91].  
Focal loss of synaptic contacts is found only in neurons bearing truncated tau. This alteration 
is seldom accompanied by focal synaptophysin immunoreactivity clustering, suggesting 
altered localization of synaptic molecules in this subpopulation of neurons. Reduced synaptic 
contacts have also been reported in tau-containing neurons in the hippocampus in AD [92], 
reinforcing the notion that reduced connectivity of neurons with NFTs may be due, in part, to 
progressive loss of synaptic inputs, leading to progressive neuronal isolation.    
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Decreased TH immunoreactivity and increased neurons with NFTs in the LC occur in AD at 
advanced stages of the disease [14, 93]. The present findings show preserved TH 
immunoreactivity in LC neurons at asymptomatic Braak stages I-IV. Reduced cortical 
noradrenergic innervation and expression of adrenergic receptors have been reported in 
symptomatic AD [14, 94-96]. Reduced noradrenergic innervation is accompanied by 
sprouting noradrenergic afferents in the hippocampus [97], and compensatory changes in 
the LC and hippocampus in advanced stages of AD [98, 99]. Interestingly, dopamine beta-
hydroxylase activity in plasma is decreased at early stages of AD, suggesting a 
compensatory mechanism for the loss of noradrenergic neurons [100].  
The present findings show increased expression levels of α2A-ARs in the hippocampus and 
amygdala at first stages of NFT pathology occurring in parallel with local decrease of TH 
protein levels. The present observations show that compensatory changes in noradrenergic 
target nuclei might occur at very early Braak stages of NFT pathology.  
The differentially expressed genes (DEG) obtained after the microarray raw data processing 
did not reach the high fold change levels commonly established for transcript selection. For 
this reason we selected those transcripts that showed the higher fold change, establishing in 
consequence as a treshold those values that showed an absolute fold change equal to or 
greater than 1.2 combined with unadjusted p-value ≤ 0.05. 
Whole transcriptome arrays have identified deregulated clusters including i)  genes encoding 
proteins linked with protein folding, chaperone binding and heat shock protein bindingwhich 
were up-regulated at stage IV when compared with stage I; ii) genes associated with ATP 
metabolism, including genes associated with ATPase activator activity and ATPase regulator 
activity which were up-regulated at stage IV when compared with stage I; iii) genes coding 
for DNA-binding proteins which were down-regulated at stage IV when compared with stage 
I; and iv) members of the small nucleolar RNAs family (SNOR) down-regulated at stage IV 
when compared with stage I.  
Representative elements of these four clusters were validated with RT-qPCR including heat 
shock protein members HSPA1A/Bis, HSPA6 (Hsp70, member 6), and DNAJB1 (HSP40) 
[101-14]. Altered expression of these genes is not unexpected as they are likely linked to 
the abnormal tau protein and folding in NFTs. ID4 (Inhibitor of DNA binding 4) encodes a 
member of the inhibitor of DNA binding protein family which acts as helix-loop-helix 
transcription factors whose activity depends on the protein binding partner [105]. Small 
nucleolar RNAs (snoRNAs), including SCARNA2 (small Cajal body-specific RNA 2), are 
non-coding RNAs which regulate post-transcriptional processing of other non-coding RNAs, 
among other functions such as microRNA-dependent gene silencing and alternative splicing 
[106-108]. The involvement of DNA binding proteins and the snoRNA family in the pathology 
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of LC in AD is relevant, as nuclear and nucleolar RNAs and proteins are emerging as key 
participants in neurodegeneration [109-111], and altered protein synthesis from the 
nucleolus to the ribosome has recently been reported in AD [112]. 
Conclusions 
The present study shows that intraneuronal deposition of hyper-phosphorylated tau and 
misfolded tau, and incorporation of truncated tau in the LC at asymptomatic early and middle 
stages of NFT pathology are accompanied by altered mitochondria, reduced intraneuronal 
haemoglobin α and β, increased oxidative stress, and reduced stress responses. This 
concurs with microglia proliferation and increased expression of AIF1, CD68, PTGS2, IL1β, 
IL6, and TNF-α. Whole transcription analysis has shown novel altered metabolic pathways in 
the LC at early stages of NFT pathology including up-regulation of genes associated with 
protein folding and chaperone binding, and genes associated with ATP metabolism, and 
down-regulation of genes coding for DNA-binding proteins and members of the small 
nucleolar RNAs family. Tyrosine hydroxylase (TH) immunoreactivity is preserved in neurons 
of LC but TH protein levels are decreased in the amygdala and hippocampus. Parallel 
increased expression levels of α2A-ARs in the hippocampus and amygdala suggest 
compensatory activation in the face of decreased adrenergic input. Although subtle changes 
in mood and wake-sleep cycle disturbances, and discrete impairment of attention and 
learning capacity, cannot be excluded in this series, present observations unveil novel 
alterations in the LC and projections in asymptomatic individuals at early and middle stages 
of NFT pathology. 
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Figure legends 
 
Figure 1: A) Percentage of neurons containing hyper-phosphorylated tau deposition as 
revealed with AT8 antibody in LC at Braak stages I, II, II and IV of NFT pathology. Mean 
values of each group were compared with one-way analysis of variance (ANOVA) followed 
by post-hoc Tukey’s multiple comparison test, and differences were considered statistically 
significant at $ p < 0.05; $$ p < 0.01; $$$ p < 0.001 compared with stage I; & p < 0.05; && p 
< 0.01; &&& p < 0.001 compared with stage II; and ~ p < 0.05; ~~ p < 0.01; ~~~ p < 0.001 
compared with stage III. B) Immunostaining of tau-positive neurons in LC using different 
anti-tau antibodies: a: tau 100; b: 3Rtau; c: 4Rtau; d: P-tauThr181; e: P-tauSer262; f: AT8; g: 
PHF; h: Alz50; i: tau-C3; bar = 25 µm. C) Double-labeling immunofluorescence and confocal 
microscopy using combinations of anti-tau antibodies and anti-ubiquitin; a-c: Alz50 (green) 
and  P-tauThr181 (red); d-f: tau-C3 (green) and  P-tauThr181 (red); g-i: ubiquitin (green) and 
P-tauThr 181 (red) in LC. c, f, i: merge. Nuclei stained with DRAQ5TM (blue); bar = 30 µm.  
 
 
Figure 2: Expression and localization of tau kinases and hyper-phosphorylated tau in LC as 
revealed by double-labeling immunofluorescence and confocal microscopy. a-c: P-
tauThr181 (green) and MAPK-ERK-P (red); d-f: AT8 (green) and SAPK-JNK-P (red); g-i: 
AT8 (green) and p38-P (red); j-l: AT8 (green) and GSK-3β-P (Ser9) (red); m-o: P-tauThr181 
(green) and GSK-P (Y279/Y216) (red); c, f, i, l, o: merge. Nuclei stained with DRAQ5TM 
(blue); bar = 50 µm.  
 
 
Figure 3: Mitochondria, oxidative stress and responses, and hemoglobin in LC. A) 
Mitochondria; a-c: Decreased VDAC (green) immunoreactivity is seen in a minority of 
neurons containing P-tauThr181 (red); d-f: VDAC immunoreactivity is decreased in neurons 
containing tau-C3 (red) arrow; c, f: merge; bar = 50 µm. B) Oxidative stress and responses; 
a-c SOD1 immunoreactivity (red) is reduced in neurons with P-tauThr181 (arrow); d-f: P-
tauThr181 (green) and neuroketal (red) co-localize in neurons; bar = 50 µm. C) Hemoglobin 
and erythropoietin receptor; a-c: Hb alpha (red) is reduced in AT8-immunoractive (green) 
neurons; d-f: Hb beta (red) immunoreactivity is also decreased in AT8-positive neurons 
(green), whereas  g-i: EPO receptor  (red) is present in tau containing neurons; bar = 50 µm. 
c, f, i: merge. Nuclei stained with DRAQ5TM (blue)  
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Figure 4: Tyrosine hydroxylase and synaptophysin in LC neurons. A) TH immunoreactivity 
(green) is expressed equally in neurons with phospho-tau immunoreactive (red) and 
negative neurons at Braak stage IV of NFT pathology; c: merge; bar = 50 µm. B) Reduced 
synaptophysin-immunoreactive dots (green) in neurons containing tau-C3-immunoreactive 
deposits (red); remaining dots are labeled with arrows; stage IV of NFT pathology; c: merge; 
bar = 20 µm. Nuclei stained with DRAQ5TM (blue).  
 
Figure 5: A) Immunohistochemistry to Iba1 in the LC at Braak stages I (a), III (B), and IV (c) 
of NFT pathology. Moderate increase in the number of Iba-1- immunoreactive cells is found 
along with disease progression; microglial cells with short, thick, and varicose branches also 
present. B) mRNA expression of AIF1 (which encodes Iba-1), CD68, PTGS2 (which 
encodes COX2), GFAP, IL1β, IL6,IL10, and TNF-α in the locus at Braak stages I, II, II, and 
IV, and in middle-aged individuals with no NFT pathology. Expression values for the distinct 
probes are normalized with combined mean values of AARS, GUS-β, HPRT1, and 
XPNPEP1. AD cases analyzed are the same as those used in whole-transcriptome arrays. 
Mean fold-change values for each group were compared with one-way analysis of variance 
(ANOVA) followed by post-hoc Tukey’s multiple comparison test and differences were 
considered statistically significant at * p < 0.05; ** p < 0.01; *** p < 0.001 compared with MA; 
$ p < 0.05; $$ p < 0.01; $$$ p < 0001 compared with stage I; & p < 0.05; && p < 0.01; &&& p 
< 0.001 compared with stage II; and ~ p < 0.05; ~~ p < 0.01; ~~~ p < 0.001 compared with 
stage III. Tendencies were considered at # p < 0.1. Moderate activation of inflammatory 
responses is manifested by increased AIF1, CD68, PTGS2, ILβ, IL6, and TNF-α with 
disease progression. GFAP and IL10 mRNA expression levels are not modified at these 
stages.  
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Fig. 6: Expression of alpha-2A adrenergic receptor (α2AAR) and tyrosine hydroxilase (TH) in 
the hippocampus and amygdala at different Braak stages of NFT pathology. Membrane 
extracts (80 μg) from human hippocampus (A) and amygdala (B) necropsies were analyzed 
with SDS-PAGE and immunoblotted using a rabbit anti-α2AAR polyclonal antibody (1 μg/ml), 
a rabbit anti-TH polyclonal antibody (1 μg/ml), and a rabbit anti-α-actinin polyclonal antibody 
(1μg/ml). A HRP-conjugated anti-rabbit IgG (1/30,000) was used as a secondary antibody. 
The immunoreactive bands were visualized with chemiluminescence. Two different 
representative human samples for each group (i.e. middle-aged individuals MA and stages I, 
II, III, and IV; see Table 1) are shown. Quantification of α2AAR and TH expression in 
hippocampus (A) and amygdala (B) membranes are shown in the lower panels. The 
immunoreactive bands corresponding to α2AAR and TH in each human sample were 
normalized with α-actinin expression. Data were normalized by the expression of α2AAR and 
TH in the control group ± SEM of 4 to 10 samples per group (MA n=10, stage I n=8, stage II 
n=4, stage III n=6, stage IV n=5; see Table 1). One-way analysis of variance (ANOVA) 
followed by post-hoc Tukey’s multiple comparison test were used; differences are 
considered statistically significant at * p < 0.05 compared with control; $ p < 0.05 and $$ p < 
0.01 compared with stage I. 
 
 
Figure 7: A) Significant gene differences are seen when comparing gene expression profiles 
in LC at Braak stages I-IV of NFT pathology. Differences between groups are considered 
statistically significant at un-adjusted p < 0.05. B) Hierarchical clustering heat map of mRNA 
array transcripts showing differential gene expression profile in LC at Braak stages I, II, III, 
and IV of NFT pathology.  
 
Figure 8: mRNA expression levels of SCARNA2, HSPA6, ID4, HSPA1A/B, and DNAJB1 in 
LC at Braak stages I, II, III, and IV of FNT pathology determined by TaqMan PCR assays. 
Expression values for the distinct probes were normalized with combined mean values of 
AARS, GUS-β, HPRT1, and XPNPEP1. Cases analyzed are the same as those used in 
whole-transcriptome arrays. Mean fold-change values of each group were compared with 
one-way analysis of variance (ANOVA) followed by post-hoc Tukey’s multiple comparison 
test and differences are considered statistically significant at * p < 0.05; ** p < 0.01; *** p < 
0.001 compared with MA; $ p < 0.05; $$ p < 0.01; $$$ p < 0001 compared with stage I; & p 
< 0.05; && p < 0.01; &&& p < 0.001 compared with stage II; and ~ p < 0.05; ~~ p < 0.01; ~~~ 
p < 0.001 compared with stage III. Tendencies are considered at # p < 0.1.  
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Supplementary figure 1: Immunoblot detection of human α2A-AR expressed in HEK-293T 
cells. HEK-293T cells were transiently transfected with cDNA encoding the α2A-AR or empty 
pcDNA3.1+ vector (mock). Increasing concentrations (1, 2, and 3 μg) of cell membrane 
extracts were analyzed with SDS-PAGE and immunoblotted using a rabbit anti-α2A-AR 
polyclonal antibody (1 μg/ml). A HRP-conjugated anti-rabbit IgG (1/30,000) was used as a 
secondary antibody. The immunoreactive bands were visualized with chemiluminescence.  
 
 
Supplementary figure 2: A) IPA analysis of top altered networks in LC and network-related 
diseases and biofunctions comparing Braak stage IV with stage I of NFT pathology. B) 
Interaction diagram of altered pathways. 
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